Secukinumab
Secukinumab is a monoclonal antibody medication that targets interleukin-17A (IL-17A), a protein involved in the inflammatory response. It is used to treat conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis by reducing inflammation and symptoms associated with these autoimmune disorders.Secukinumab is indicated for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis in adult patients who have not responded adequately to conventional therapies.
The recommended dosage of secukinumab varies depending on the condition being treated and the patient's weight. Typically, it is administered by subcutaneous injection at specific intervals, as prescribed by a healthcare professional.
Secukinumab is contraindicated in patients with a known hypersensitivity to the active substance or any of the excipients in the formulation. It should also be avoided in patients with active infections.
Before initiating treatment with secukinumab, healthcare providers should assess patients for tuberculosis (TB) infection, as the medication may increase the risk of TB reactivation. Additionally, patients should be monitored for signs of infection during treatment.
Common side effects of secukinumab may include upper respiratory tract infections, headache, diarrhea, and injection site reactions. Serious side effects such as severe infections and allergic reactions are possible but rare.
There are no known drug interactions with secukinumab. However, patients should inform their healthcare provider about all medications, including over-the-counter drugs and supplements, before starting treatment.
